2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2016
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States
Sweet DE, Altice FL, Cohen CJ, Vandewalle B. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLOS ONE 2016, 11: e0147821. PMID: 26808503, PMCID: PMC4725959, DOI: 10.1371/journal.pone.0147821.Peer-Reviewed Original ResearchConceptsSingle-tablet regimensSubstantial price reductionsTenofovir disoproxil fumarate/emtricitabineCost-effectiveness thresholdIncremental cost-effectiveness ratioGeneric medicationsDaily single-tablet regimensDisoproxil fumarate/emtricitabineCost-effectiveness ratioElvitegravir/cobicistatCombination antiretroviral therapyHIV-1 patientsSingle-tablet regimenHigher inpatient costsHIV-1 infectionIncremental lifetime costPrice reductionEconomic outcomesMicrosimulation modelSuch policiesGeneric lamivudineTablet regimensAntiretroviral therapyU.S. settingsComplex regimens
2015
Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States
Song DL, Altice FL, Copenhaver MM, Long EF. Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States. PLOS ONE 2015, 10: e0116694. PMID: 25658949, PMCID: PMC4320073, DOI: 10.1371/journal.pone.0116694.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsOpioid substitution therapyHIV infectionHIV incidenceHIV prevalenceEvidence-based risk reduction interventionDynamic HIV transmission modelHolistic Health Recovery ProgramBehavioral HIV prevention interventionsFuture HIV incidenceTotal medical costsHIV transmission modelHIV prevention interventionsGeneral adult populationRisk reduction interventionsCost-effectiveness analysisSubstitution therapySexual transmissionHIV programsPrevention interventionsMedical costsTreatment settingsLife yearsReduction interventionsUS population
2014
Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimens
2012
A Systematic Review of Antiretroviral Adherence Interventions for HIV-Infected People Who Use Drugs
Binford MC, Kahana SY, Altice FL. A Systematic Review of Antiretroviral Adherence Interventions for HIV-Infected People Who Use Drugs. Current HIV/AIDS Reports 2012, 9: 287-312. PMID: 22936463, PMCID: PMC3495269, DOI: 10.1007/s11904-012-0134-8.Peer-Reviewed Original ResearchConceptsMedication-assisted therapyCART adherenceVirologic outcomesSystematic reviewCombination antiretroviral therapy (cART) adherenceAntiretroviral Adherence InterventionPost-intervention adherenceHIV treatment outcomesHIV clinical careAntiretroviral therapy adherenceNurse-delivered interventionShort-term adherenceCognitive behavioral therapyLong-term improvementPeer-driven interventionVirologic benefitAntiretroviral therapyDevelopment of interventionsIntervention cessationAdherence interventionsProspective studyTherapy adherenceEligible studiesTreatment outcomesClinical care
2011
HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study
Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R. HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s22-s32. PMID: 21317590, PMCID: PMC3263431, DOI: 10.1097/qai.0b013e318209751e.Peer-Reviewed Original ResearchConceptsBUP/NXHIV treatment outcomesCD4 lymphocyte countHIV clinical care settingsAntiretroviral therapyViral suppressionLymphocyte countTreatment outcomesClinical care settingsOpioid dependenceCare settingsLower HIV-1 RNA levelsBuprenorphine/naloxone treatmentHIV-1 RNA levelsInitiation of ARTHIV-1 RNA suppressionComorbid substance use disorderHealth qualityBuprenorphine/naloxoneMultidisciplinary treatment strategyOpioid-dependent patientsGeneral health qualityMental health qualityOpioid-dependent subjectsSubstance use disordersMedication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research
Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011, 25: 279-290. PMID: 21239892, DOI: 10.1097/qad.0b013e328340feb0.Peer-Reviewed Original ResearchConceptsClinical outcomesPrescribed therapyFuture clinical careSuboptimal persistenceVirological failureAntiretroviral resistanceMedication persistenceHIV infectionMedication treatmentHIV treatmentCertain regimensClinical consequencesClinical carePatient behaviorPatientsContinuous treatmentUnderrecognized aspectsTherapyAdherenceHIVTreatmentShort durationCurrent literatureDurationIntervention
2010
A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization
Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug And Alcohol Dependence 2010, 112: 178-193. PMID: 20705402, PMCID: PMC2997193, DOI: 10.1016/j.drugalcdep.2010.06.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHealth care utilizationHIV treatment outcomesAlcohol use disorderPoor HIV treatment outcomesCare utilizationTreatment outcomesAntiretroviral therapyUse disordersImpact of AUDHealth service utilizationHIV/AIDSCD4 countHIV statusMedication adherenceService utilizationDATA SYNTHESISAnimal studiesElectronic databasesSystematic reviewAlcohol useTherapyPrimary articlesGoogle ScholarAdherenceOutcomesDAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions
Altice FL, Springer SA. DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions. JAMA Internal Medicine 2010, 170: 109-110. PMID: 20065210, PMCID: PMC2825565, DOI: 10.1001/archinternmed.2009.459.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAdministration, OralAdolescentAdultAgedAnti-HIV AgentsDeoxycytidineDose-Response Relationship, DrugDrug Resistance, ViralEmtricitabineFemaleGenotypeHIV InfectionsHIV-1HumansLopinavirMaleMiddle AgedOrganophosphonatesPatient CompliancePyrimidinonesRandomized Controlled Trials as TopicRNA, ViralStavudineTenofovirTreatment OutcomeYoung Adult
2009
Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy
Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009, 21: 976-983. PMID: 20024753, PMCID: PMC2797133, DOI: 10.1080/09540120802657555.Peer-Reviewed Original ResearchConceptsInjection drug usersCES-D scoresMajor depressive disorderAntiretroviral therapyCD4 countDepressive symptomsDrug usersDrug useHIV-1 RNA levelsProspective clinical trialsSubstance abuse treatment servicesSelf-administered therapyActive drug useNon-Caucasian raceSix-month followSix-month dataAntidepressant medicationAntiretroviral treatmentPoor adherenceSymptomatic responseMale genderClinical trialsDepressive disorderDepression ScaleDrug treatmentPersistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial
Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 176-181. PMID: 19131891, PMCID: PMC2670996, DOI: 10.1097/qai.0b013e3181938e7e.Peer-Reviewed Original ResearchConceptsSelf-administered therapyHIV-1 RNACD4 lymphocyte countVirological successDrug usersAntiretroviral therapyLymphocyte countMonths postinterventionLog10 HIV-1 RNAProportion of subjectsActive drug usersVirological benefitVirological outcomesSecondary outcomesControlled TrialsPrimary outcomeBlood samplesDAARTMultivariate analysisBenefits persistTherapyTrialsAdditional strategiesOutcomesPostintervention
2007
Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy
Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS And Behavior 2007, 12: 284-293. PMID: 18085432, PMCID: PMC2693908, DOI: 10.1007/s10461-007-9336-2.Peer-Reviewed Original ResearchConceptsSelf-administered therapyAntiretroviral therapyDrug usersComposite adherence scorePresence of depressionDrug treatment programsControlled TrialsSix-month periodAdherence scoreOwn medicationsHealth outcomesDAARTMajor causeTherapyAdherenceDiscontinuationHIVSuccessful program designTrialsParticipantsHospitalizationMedicationsLack of willingnessVisitsDirectly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance
Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsNew drug resistance mutationsSelf-administered therapyDrug usersAntiretroviral therapyHIV genotypic resistance testingFuture drug optionsAntiretroviral drug resistanceGenotypic resistance testingGenotypic sensitivity scoreMain outcome measuresMedication resistanceModified intentionVirologic benefitAntiretroviral resistanceTreat analysisClinical outcomesDrug mutationsDrug optionsOutcome measuresAdjusted probabilityDrug resistanceResistance mutationsHIVEffective interventionsSuperiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean changeAntiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory dataHIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications
Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. International Journal Of Drug Policy 2007, 18: 326-328. PMID: 17689382, PMCID: PMC2084072, DOI: 10.1016/j.drugpo.2006.12.011.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance therapyInjection drug useAnti-retroviral therapySubstitution therapyDrug useAddition of methadoneAdministration of buprenorphineHIV-1 seropositivityOpiate substitution therapyOverall health outcomesIllicit drug useCost of buprenorphineHIV treatment accessMaintenance therapyOpioid dependenceHIV casesEntry criteriaTreatment accessBuprenorphineDrug usersHealth outcomesMultidisciplinary teamTherapyGlobal Fund resourcesAdministration
2006
Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users
Smith-Rohrberg D, Mezger J, Walton M, Bruce RD, Altice FL. Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s48-s53. PMID: 17133204, DOI: 10.1097/01.qai.0000248338.74943.85.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsVirologic outcomesCase management servicesDrug usersVirologic successService utilizationRNA levelsHigher medical service utilizationHIV-1 RNA reductionLog10 HIV-1 RNAAntiretroviral Therapy (SMART) trialImproved virologic outcomesHealth service utilizationHIV-1 RNASelf-administered therapyCopies/mLMedical service utilizationActive drug usersSubstance abuse servicesAntiretroviral therapyHIV outcomesPrimary outcomeProblematic adherenceTherapy trialsDAART
2004
Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical servicesEffectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases 2004, 38: 1754-1760. PMID: 15227623, DOI: 10.1086/421392.Peer-Reviewed Original ResearchConceptsMean CD4 lymphocyte countCD4 lymphocyte countAntiretroviral therapyLymphocyte countCopies/Sustained benefitHuman immunodeficiency virus type 1 RNA levelsActive antiretroviral therapyRetrospective cohort studyLog10 copies/Mu LHAART useCohort studyHIV diseaseLymphocyte responsesPoor outcomeIncarcerated patientsRNA levelsLaboratory dataTherapyCorrectional settingsIncarceration periodsOutcomesPeriod of incarcerationCount